January 25-27, 2022 | Digital Event

With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.

Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.

Here’s what you can look forward to:

• Get clinical updates on current bispecific antibody approaches from Laura Codari Deak (Roche Innovation Center), Michelle Morrow (F-Star Biotechnology) and Paul Moore (Macrogenics)
• Take a look at the potential of LAG-3 in haematological cancers with Segundo Rodriguez (Universidad de Oviedo)
• Explore the mechanism of action and understand how LAG-3 mediates its inhibitory function with Creg Workman (University of Pittsburgh)
• Understand how LAG-3 acts in non-oncological conditions with our interactive online workshop with Jon Piganelli (University of Pittsburgh)